In VivoAs people everywhere continue to face uncertainties and challenges during the COVID-19 pandemic, rates of depression, anxiety and feelings of hopelessness are also on the rise. According to a poll by
Medtech InsightNexstim PLC is taking its neuromodulation depression therapy to the Australian market following regulatory approval. The Finnish company has received a medical device licence from the Australian Gove
Medtech InsightNexstim PLC is bringing its neuromodulation depression therapy to the Canadian market after signing an exclusive distribution agreement with Canadian Health Solutions (CHS). The Helsinki-based compan
Medtech InsightNexstim PLC has filed a 510(k) to US FDA for its NBT (Navigated Brain Therapy) transcranial magnetic stimulation (TMS) therapy system to be cleared for treating major depressive disorder. Major de